Study | N | F/M | Age (Mean) | Histology (N) | TNM Stage (N) | Quality of Life | Invention Group (N) | Group 1 (N) | Group 2 (N) | End point |
---|---|---|---|---|---|---|---|---|---|---|
Wang JW 2005[11] | 486 | 140/346 | 18-75 | SCC (129) LAC (165) Others (28) | IIIA (51) IIIB (81) IV (185) | ECGO | NPE versus NP + placebo | 322 | 164 | RR, DCR, TTP, SI, AEs |
Yang L 2005[12] | 87 | 28/59 | 37-76 | SCC (34) LAC (50) Others (3) | III (32) IV (55) | ECGO | NPE versus NP | 57 | 33 | RR, DCR, SI, AEs |
Cai L 2007[13] | 71 | 25/46 | NA | SCC (27) LAC (32) Others (12) | IIIA (9) IIIB (33) IV (29) | KPS | NPE versus NP | 39 | 32 | RR, DCR, AEs |
Mu HY 2009[14] | 62 | 22/40 | 42-75 | SCC (28) LAC (34) | IIIB (28) IV (34) | KPS | NPE versus NP (16) TPE versus TP (6) PPE versus PP (8) | 32 | 30 | RR, DCR, SI, AEs |
Liao HY 2009[15] | 85 | 32/53 | 36-72 | SCC (36) LAC (49) | IIIB (32) IV (53) | KPS | GPE versus GP | 30 | 55 | RR, DCR, OYS, AEs |
Zang T 2009[16] | 104 | 36/68 | 42-68 | NA | IIIB (58) IV (46) | ECGO | GPE versus GP | 48 | 56 | RR, DCR, SI, AEs |
Liu J 2009[17] | 62 | 17/45 | 29-68 | SCC (38) LAC (24) | III (37) IV (25) | KPS | NPE + RT versus NP + RT | 31 | 31 | RR, DCR, TTP, AEs |
Ma JB 2009[18] | 46 | 11/35 | 38-73 | SCC (31) LAC (15) | IIIA (26) IIIB (20) | ECGO | NPE + RT versus NP + RT | 23 | 23 | RR, DCR, TTP, AEs |
Shi GY 2009[19] | 462 | 162/300 | 20-74 | SCC (190) LAC (252) Others (20) | IIIA (92) IIIB (144) IV (226) | ECGO | GPE versus GP | 308 | 154 | RR, DCR, TTP, SI, AEs |
Han BH 2011[20] | 122 | 35/87 | 28-78 | SCC (37) LAC (78) Others (7) | IIIB (43) IV (79) | ECGO | TCE versus TC + placebo | 61 | 61 | RR, DCR, AEs |
Zhao X 2011[21] | 69 | 23/46 | 35-73 | SCC (34) LAC (25) Others(10) | IIIB (11) IV (58) | ECGO | GPE versus GP | 33 | 36 | RR, DCR, AEs |
Hu HT 2011[22] | 89 | 21/68 | 41-70 | SCLC (89) | NA | KPS | TPE versus TP | 45 | 44 | RR, DCR, AEs |
Wen F 2011[23] | 84 | 27/57 | 54-75 | SCC (36) LAC (44) Others (4) | NA | KPS | NPE versus NP | 43 | 41 | RR, DCR, AEs |
Zhang H 2011[24] | 56 | 15/41 | 36-75 | SCC (18) LAC (33) Others (5) | IIIB (32) IV (25) | KPS | NPE versus NP (2) GPE versus GP (15) TPE versus TP (11) | 28 | 28 | RR, DCR, TTP, OYS, AEs |
Chen Q 2011[25] | 68 | 27/41 | 42-75 | SCC (20) LAC (44) Others (4) | IIIA (15) IIIB (41) IV (12) | NA | GPE versus GP | 33 | 35 | RR, DCR, SI |